Ovarian Cancer
2,068
350
470
920
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
310 trials with published results (15%)
Research Maturity
920 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.7%
242 terminated out of 2068 trials
79.2%
-7.4% vs benchmark
8%
170 trials in Phase 3/4
34%
310 of 920 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 920 completed trials
Clinical Trials (2068)
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
Ovarian Cancer Identification on CT Using Deep Learning
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Study of PHST001 in Advanced Solid Tumors
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
A Study of MGC026 in Participants With Advanced Solid Tumors
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Implementation of New Models of Ovarian Carcinoma Resistant to Therapy
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies